awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34538361-5810C399-B966-4E89-B470-CB58DE784B2B
Q34538361-5810C399-B966-4E89-B470-CB58DE784B2B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34538361-5810C399-B966-4E89-B470-CB58DE784B2B
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
P2860
Q34538361-5810C399-B966-4E89-B470-CB58DE784B2B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34538361-5810C399-B966-4E89-B470-CB58DE784B2B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1b62e9aea96f594807d484dde18d1a751d6fa42d
P2860
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.